Seaport Therapeutics, Inc. (SPTX) News
Follow Seaport Therapeutics, Inc. (SPTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Seaport Therapeutics Initiated at Strong Buy by Raymond James
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 11:33 AM UTC
L
Seaport Therapeutics price target maintained at $50.00 by HC Wainwright
HC Wainwright & Co maintained its $50.00-per-share price target for Seaport Therapeutics, according to Benzinga’s ratings actions cited via TradingView News.
EQUITY | Sep 10, 2026, 10:53 AM UTC
L
SPTX outlines Glyph platform oral-therapy progress for depression, anxiety
SPTX says its Glyph platform targets oral bioavailability and liver-toxicity challenges. Lead programs GlyphAllo and GlyphAgo target depression and anxiety, with registration-enabling trials planned.
EQUITY | Sep 09, 2026, 06:34 PM UTC
M
SPTX outlines Glyph platform progress for oral neuropsychiatric therapies
SPTX presented its neuroscience pipeline, saying the Glyph platform can improve drug bioavailability and safety. Lead programs GlyphAllo and GlyphAgo target depression and anxiety, with promising clinical data and upcomi
EQUITY | Sep 09, 2026, 06:04 PM UTC
L
PureTech-linked Seaport Therapeutics reports positive Phase 1 results
PureTech Health says Seaport Therapeutics has reported positive Phase 1 driving trial results for GlyphAllo.
EQUITY | Sep 09, 2026, 05:19 PM UTC
M
PureTech’s PRTC reports positive Phase 1 GlyphAllo topline results
PureTech Health plc says Seaport Therapeutics has reported positive topline Phase 1 results from a GlyphAllo simulation trial in healthy volunteers.
EQUITY | Sep 09, 2026, 05:00 PM UTC
L
SPTX advances oral neuropsychiatric therapies toward pivotal trials
SPTX is advancing novel neuropsychiatric treatments using the Glyph™ platform to enhance oral bioavailability and safety. Lead candidates for depression and anxiety have shown strong early results, with key data readouts
EQUITY | Sep 09, 2026, 04:46 PM UTC
M
Seaport Therapeutics reports positive GlyphAllo Phase 1 topline results
Seaport Therapeutics said it announced positive topline results from a Phase 1 Driving Simulation Trial of GlyphAllo in healthy volunteers. GlyphAllo is listed as SPT-300.
EQUITY | Sep 09, 2026, 11:00 AM UTC
L
Seaport Therapeutics initiated Buy by Jones Trading
TradingView News reports Jones Trading initiated coverage on Seaport Therapeutics with a Buy rating.
EQUITY | Aug 26, 2026, 03:26 PM UTC
L
SPTX: Hombach Sells
Seaport Therapeutics director Robert J.P. Hombach sells 13,000 shares
EQUITY | Jun 24, 2026, 10:08 AM UTC